TM & Partners has assisted Oasmia Pharmaceutical in relation to its acquisition of the global development and commercialization rights for Cantrixil

TM & Partners has assisted Oasmia Pharmaceutical (Oasmia) in relation to its acquisition of the global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program. The transaction includes an upfront payment of $4 million, milestone payments worth up to $42 million and sales-based royalties. The Australian law firm Allens and TM & Partners advised Oasmia in relation to the transaction.

TM & Partners’ team included Johan Wigh, Fredrik Gustafsson and Alexandra Rosell.